Table 1. Baseline Demographic Characteristics, Comorbidities, and Disease Characteristics.
| Characteristic | No. (%) | Difference (95% CI)a | ||
|---|---|---|---|---|
| All participants (N = 27) | Timolol thermosensitive gel (n = 14) | Placebo thermosensitive gel (n = 13) | ||
| Age, median (range), y | 55 (20 to 76) | 58 (20 to 76) | 52 (30 to 65) | −6 (−17 to 2) |
| Sex | ||||
| Men | 13 (48) | 4 (29) | 9 (69) | 41 (3 to 65) |
| Women | 14 (52) | 10 (71) | 4 (31) | |
| Race/ethnicity | ||||
| White | 25 (93) | 14 (100) | 11 (85) | −15 (−42 to 9) |
| Black | 2 (7) | 0 | 2 (15) | |
| Comorbidities | ||||
| Hypertension | 6 (22) | 4 (31) | 2 (18) | −13 (−42 to 22) |
| Seasonal allergies | 18 (67) | 9 (69) | 9 (82) | 13 (−22 to 42) |
| Comorbidity status | ||||
| None | 17 (63) | 9 (64) | 8 (62) | −3 (−35 to 30) |
| Mild | 7 (26) | 3 (21) | 4 (31) | 9 (−22 to 40) |
| Moderate | 1 (4) | 1 (7) | 0 | −7 (−31 to 16) |
| Severe | 2 (7) | 1 (7) | 1 (8) | 0 (−25 to 27) |
| Current smoker | 4 (15) | 2 (14) | 2 (15) | 1 (−27 to 30) |
| Current nasal perforation | 5 (19) | 4 (29) | 1 (8) | −21 (−48 to 10) |
| Past epistaxis treatments | ||||
| Cautery | 19 (70) | 11 (79) | 8 (62) | −17 (−47 to 16) |
| Sclerotherapy | 16 (59) | 8 (57) | 8 (62) | 4 (−29 to 37) |
| Doxycycline | 1 (4) | 1 (7) | 0 | −7 (−31 to 16) |
| Septodermoplasty | 1 (4) | 1 (7) | 0 | −7 (−31 to 16) |
| Other nose/sinus surgery | 7 (26) | 3 (21) | 4 (31) | −21 (−22 to 40) |
| Baseline Clinical Global Impression–Severity Score | ||||
| No problem | 0 | 0 | 0 | 0 (−23 to 23) |
| Mild problem | 7 (27) | 3 (23) | 4 (31) | 8 (−25 to 38) |
| Moderate/severe problem | 19 (73) | 10 (77) | 5 (69) | −21 (−54 to 16) |
| Problem as bad as it could be | 0 | 0 | 0 | 0 (−23 to 23) |
a
Proportion difference for categorical data and median difference for continuous data.